Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/37726
Title: | Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI An Individual Patient-Level Meta-Analysis | Authors: | Valgimigli, M Mehran, R Franzone, A da Costa, BR Baber, U Piccolo, R McFadden, EP VRANCKX, Pascal Angiolillo, DJ Leonardi, S Cao, D Dangas, GD Mehta, SR Serruys, PW Gibson, CM Steg, GP Sharma , SK Hamm, C Shlofmitz, R Liebetrau, C Briguori, C Janssens, L Huber, K Ferrario, M Kunadian, V Cohen, DJ Zurakowski, A Oldroyd, KG Han, YL Dudek, D Sartori, S Kirkham, B Escaned, J Heg, D Windecker, S Pocock, S Juni, P |
Issue Date: | 2021 | Publisher: | ELSEVIER SCIENCE INC | Source: | JACC: cardiovascular interventions (Print), 14 (4) , p. 444 -456 | Abstract: | OBJECTIVES The aim of this study was to compare ticagrelor monotherapy with dual-antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with drug-eluting stents.BACKGROUND The role of abbreviated DAPT followed by an oral P2Y(12) inhibitor after PCI remains uncertain.METHODS Two randomized trials, including 14,628 patients undergoing PCI, comparing ticagrelor monotherapy with standard DAPT on centrally adjudicated endpoints were identified, and individual patient data were analyzed using 1-step fixed-effect models. The protocol was registered in PROSPERO (CRD42019143120). The primary outcomes were the composite of Bleeding Academic Research Consortium type 3 or 5 bleeding tested for superiority and, if met, the composite of all-cause death, myocardial infarction, or stroke at 1 year, tested for noninferiority against a margin of 1.25 on a hazard ratio (HR) scale.RESULTS Bleeding Academic Research Consortium type 3 or 5 bleeding occurred in fewer patients with ticagrelor than DAPT (0.9% vs. 1.7%, respectively; HR: 0.56; 95% confidence interval [CI]: 0.41 to 0.75; p < 0.001). The composite of all-cause death, myocardial infarction, or stroke occurred in 231 patients (3.2%) with ticagrelor and in 254 patients (3.5%) with DAPT (HR: 0.92; 95% CI: 0.76 to 1.10; p < 0.001 for noninferiority). Ticagrelor was associated with lower risk for all-cause (HR: 0.71; 95% CI: 0.52 to 0.96; p = 0.027) and cardiovascular (HR: 0.68; 95% CI: 0.47 to 0.99; p = 0.044) mortality. Rates of myocardial infarction (2.01% vs. 2.05%; p = 0.88), stent thrombosis (0.29% vs. 0.38%; p = 0.32), and stroke (0.47% vs. 0.36%; p = 0.30) were similar.CONCLUSIONS Ticagrelor monotherapy was associated with a lower risk for major bleeding compared with standard DAPT, without a concomitant increase in ischemic events. (C) 2021 by the American College of Cardiology Foundation. | Keywords: | aspirin;DAPT;meta-analysis;P2Y(12) inhibitors;ticagrelor | Document URI: | http://hdl.handle.net/1942/37726 | ISSN: | 1936-8798 | e-ISSN: | 1876-7605 | DOI: | 10.1016/j.jcin.2020.11.046 | ISI #: | 000632036700014 | Rights: | 2021 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION PUBLISHED BY ELSEVIER | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI.pdf | Published version | 1.18 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.